Kumaraguru Raja
Stock Analyst at Brookline Capital
(0.39)
# 4,245
Out of 5,090 analysts
16
Total ratings
28.57%
Success rate
-22.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INTS Intensity Therapeutics | Upgrades: Buy | $3 | $0.50 | +501.56% | 1 | Aug 12, 2025 | |
| PALI Palisade Bio | Maintains: Buy | $16 | $1.79 | +796.36% | 2 | May 13, 2025 | |
| QNCX Quince Therapeutics | Initiates: Buy | $9 | $3.86 | +133.16% | 1 | Dec 18, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $3.93 | +103.56% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $19.73 | +406.84% | 2 | May 30, 2024 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $1.96 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $150 | $0.32 | +46,907.21% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $1.88 | +697.87% | 1 | Jun 29, 2023 | |
| RAIN Rain Enhancement Technologies Holdco | Reinstates: Buy | $21 | $5.68 | +269.72% | 1 | Jan 31, 2023 | |
| MNPR Monopar Therapeutics | Reinstates: Buy | $90 | $81.00 | +11.11% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $290 → $310 | $2.50 | +12,299.50% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33,600 | $2.70 | +1,244,344.44% | 1 | Sep 21, 2021 |
Intensity Therapeutics
Aug 12, 2025
Upgrades: Buy
Price Target: $3
Current: $0.50
Upside: +501.56%
Palisade Bio
May 13, 2025
Maintains: Buy
Price Target: $16
Current: $1.79
Upside: +796.36%
Quince Therapeutics
Dec 18, 2024
Initiates: Buy
Price Target: $9
Current: $3.86
Upside: +133.16%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $3.93
Upside: +103.56%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $19.73
Upside: +406.84%
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.96
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $150
Current: $0.32
Upside: +46,907.21%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $1.88
Upside: +697.87%
Rain Enhancement Technologies Holdco
Jan 31, 2023
Reinstates: Buy
Price Target: $21
Current: $5.68
Upside: +269.72%
Monopar Therapeutics
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $81.00
Upside: +11.11%
May 18, 2022
Maintains: Buy
Price Target: $290 → $310
Current: $2.50
Upside: +12,299.50%
Sep 21, 2021
Initiates: Buy
Price Target: $33,600
Current: $2.70
Upside: +1,244,344.44%